Interestingly, blast percentage was significantly higher in BC patients expressing Cobll1+/SH3BP1+ and Cobll1+/PACSIN2+/SH3BP1+ than in those with no expression (Cobll1−/PACSIN2−/SH3BP1−) (Table 1; Figure 6D). Here, SH3BP1 is linked to breast cancer.